Circulating ACE2-expressing extracellular vesicles block broad strains of SARS-CoV-2 DOI Creative Commons
Lamiaa El-Shennawy, Andrew D. Hoffmann, Nurmaa K. Dashzeveg

et al.

Nature Communications, Journal Year: 2022, Volume and Issue: 13(1)

Published: Jan. 20, 2022

Abstract The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused the pandemic of induced disease 2019 (COVID-19) with evolving variants concern. It remains urgent to identify novel approaches against broad strains SARS-CoV-2, which infect host cells via entry receptor angiotensin-converting enzyme (ACE2). Herein, we report an increase in circulating extracellular vesicles (EVs) that express ACE2 (evACE2) plasma COVID-19 patients, levels are associated pathogenesis. Importantly, evACE2 isolated from human or neutralizes SARS-CoV-2 infection by competing cellular ACE2. Compared vesicle-free recombinant (rhACE2), shows a 135-fold higher potency blocking binding viral spike protein RBD, and 60- 80-fold efficacy preventing infections both pseudotyped authentic SARS-CoV-2. Consistently, protects hACE2 transgenic mice SARS-CoV-2-induced lung injury mortality. Furthermore, inhibits (α, β, δ) equal than for wildtype strain, supporting broad-spectrum antiviral mechanism therapeutic development block existing future coronaviruses use receptor.

Language: Английский

COVID-19 Vaccine: A comprehensive status report DOI Open Access
Simran Kaur, Vandana Gupta

Virus Research, Journal Year: 2020, Volume and Issue: 288, P. 198114 - 198114

Published: Aug. 12, 2020

Language: Английский

Citations

853
SARS-CoV-2: Structure, Biology, and Structure-Based Therapeutics Development DOI Creative Commons

Mei-Yue Wang,

Rong Zhao,

Lijuan Gao

et al.

Frontiers in Cellular and Infection Microbiology, Journal Year: 2020, Volume and Issue: 10

Published: Nov. 25, 2020

The pandemic of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been posing great threats to world in many aspects. Effective therapeutic and preventive approaches including drugs vaccines are still unavailable although they development. Comprehensive understandings on life logic SARS-CoV-2 interaction virus with hosts fundamentally important fight against SARS-CoV-2. In this review, we briefly summarized current advances research, epidemic situation epidemiological characteristics caused disease COVID-19. We further discussed biology SARS-CoV-2, origin, evolution, receptor recognition mechanism And particularly, introduced protein structures structure-based therapeutics development antibodies, antiviral compounds, vaccines, indicated limitations perspectives research. wish information provided by review may be helpful global battle infection.

Language: Английский

Citations

835
Recent Developments on Therapeutic and Diagnostic Approaches for COVID-19 DOI Creative Commons
Joydeb Majumder, Tamara Minko

The AAPS Journal, Journal Year: 2021, Volume and Issue: 23(1)

Published: Jan. 1, 2021

The ongoing pandemic of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome 2 (SARS-CoV-2) has made a serious public health threat worldwide with millions people at risk in growing number countries. Though there are no clinically approved antiviral drugs and vaccines for COVID-19, attempts clinical trials several known drugs, their combination, as well development patients confirmed COVID-19. This review focuses on latest approaches to diagnostics therapy We have summarized recent progress conventional therapeutics such vaccines, anti-SARS-CoV-2 antibody treatments, convalescent plasma which currently under extensive research treatment developments nanoparticle-based therapeutic diagnostic been also discussed assessed literature data this topic summary current future perspectives.

Language: Английский

Citations

439
COVID-19: Specific and Non-Specific Clinical Manifestations and Symptoms: The Current State of Knowledge DOI Open Access
Jacek Baj, Hanna Karakuła‐Juchnowicz, Grzegorz Teresiński

et al.

Journal of Clinical Medicine, Journal Year: 2020, Volume and Issue: 9(6), P. 1753 - 1753

Published: June 5, 2020

Coronavirus disease 2019 (COVID-19), due to the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has become an epidemiological threat and a worldwide concern. SARS-CoV-2 spread 210 countries more than 6,500,000 confirmed cases 384,643 deaths have been reported, while number of both fatal is continually increasing. COVID-19 viral that can affect every age group-from infants elderly-resulting in wide spectrum various clinical manifestations. might present different degrees severity-from mild or even asymptomatic carriers, cases. The most common complications include pneumonia distress syndrome. Fever, dry cough, muscle weakness, chest pain are prevalent typical symptoms COVID-19. However, patients also atypical occur alone, which indicate possible infection. aim this paper review summarize all findings regarding manifestations patients, respiratory, neurological, olfactory gustatory, gastrointestinal, ophthalmic, dermatological, cardiac, rheumatologic manifestations, as well specific pediatric patients.

Language: Английский

Citations

420
The emergence of COVID-19 as a global pandemic: Understanding the epidemiology, immune response and potential therapeutic targets of SARS-CoV-2 DOI Open Access
Shibi Muralidar, Senthil Visaga Ambi, Saravanan Sekaran

et al.

Biochimie, Journal Year: 2020, Volume and Issue: 179, P. 85 - 100

Published: Sept. 22, 2020

Language: Английский

Citations

312
SARS-CoV-2/COVID-19: Viral Genomics, Epidemiology, Vaccines, and Therapeutic Interventions DOI Creative Commons
Mohammed Uddin, Farah Mustafa, Tahir A. Rizvi

et al.

Viruses, Journal Year: 2020, Volume and Issue: 12(5), P. 526 - 526

Published: May 10, 2020

The COVID-19 pandemic is due to infection caused by the novel SARS-CoV-2 virus that impacts lower respiratory tract. spectrum of symptoms ranges from asymptomatic infections mild lethal form which associated with severe pneumonia, acute distress, and fatality. To address this global crisis, up-to-date information on viral genomics transcriptomics crucial for understanding origins dispersion virus, providing insights into pathogenicity, transmission, epidemiology, enabling strategies therapeutic interventions, drug discovery, vaccine development. Therefore, review provides a comprehensive overview genomic etiology, findings recent transcriptomic map analysis, viral-human protein interactions, molecular diagnostics, current status intervention Moreover, we provide an extensive list resources will help scientific community access numerous types databases related OMICs approaches therapeutics treatment.

Language: Английский

Citations

293
An update on COVID-19 pandemic: the epidemiology, pathogenesis, prevention and treatment strategies DOI
Hin Fung Tsang, Lawrence Chan, William C. Cho

et al.

Expert Review of Anti-infective Therapy, Journal Year: 2020, Volume and Issue: 19(7), P. 877 - 888

Published: Dec. 12, 2020

To date, the transmission of Coronavirus Disease-2019 (COVID-19) is still uncontrollable with fact that numbers confirmed and death cases are increasing. Up to 1st October 2020, 33,842,281 1,010,634 deaths have been reported World Health Organization from 216 different countries, areas territories. Despite urgent demand for effective treatment strategies, there no specific antiviral COVID-19 guidelines vary between countries.In this article, we summarized current knowledge on pandemic worldwide. Moreover, epidemiology, pathogenesis, prevention options will be discussed so shall prepare ourselves better fight severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).The situation unpredictable. There vaccine or anti-viral drug treat serve patients. Combination therapies shown promising clinical improvement. Repurposing FDA-approved drugs might one possible options. Without vaccines COVID-19, most way prevent being infected generate an ecosystem protection, precautions preventive measures.

Language: Английский

Citations

289
Rapid inactivation of SARS-CoV-2 with deep-UV LED irradiation DOI Creative Commons
Hiroko Inagaki, Akatsuki Saito,

Hironobu Sugiyama

et al.

Emerging Microbes & Infections, Journal Year: 2020, Volume and Issue: 9(1), P. 1744 - 1747

Published: Jan. 1, 2020

The spread of novel coronavirus disease 2019 (COVID-19) infections worldwide has raised concerns about the prevention and control SARS-CoV-2. Devices that rapidly inactivate viruses can reduce chance infection through aerosols contact transmission. This in vitro study demonstrated irradiation with a deep ultraviolet light-emitting diode (DUV-LED) 280 ± 5 nm wavelength inactivates SARS-CoV-2 obtained from COVID-19 patient. Development devices equipped DUV-LED is expected to prevent virus invasion air after touching contaminated objects.

Language: Английский

Citations

286
Clinical and pathological investigation of patients with severe COVID-19 DOI Creative Commons

Shaohua Li,

Lina Jiang, Xi Li

et al.

JCI Insight, Journal Year: 2020, Volume and Issue: 5(12)

Published: May 19, 2020

BACKGROUND. Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory coronavirus 2 (SARS-CoV-2), has become a pandemic. This study addresses the clinical and immunopathological characteristics of COVID-19.

Language: Английский

Citations

276
COVID-19: Characteristics and Therapeutics DOI Creative Commons
Rameswari Chilamakuri, Saurabh Agarwal

Cells, Journal Year: 2021, Volume and Issue: 10(2), P. 206 - 206

Published: Jan. 21, 2021

Novel coronavirus (COVID-19 or 2019-nCoV SARS-CoV-2), which suddenly emerged in December 2019 is still haunting the entire human race and has affected not only healthcare system but also global socioeconomic balances. COVID-19 was quickly designated as a pandemic by World Health Organization there have been about 98.0 million confirmed cases 2.0 deaths, of January 2021. Although, our understanding significantly increased since its outbreak, multiple treatment approaches pharmacological interventions tested are currently under development to mitigate risk-factors. Recently, some vaccine candidates showed around 95% clinical efficacy, now receiving emergency use approvals different countries. US FDA recently approved BNT162 mRNA-1273 vaccines developed Pfizer/BioNTech Moderna Inc. for vaccination USA. In this review, we present succinct overview SARS-CoV-2 virus structure, molecular mechanisms infection, epidemiology, diagnosis, manifestations. We systematize strategies trials initiated after based on viral infection replication mechanisms. Additionally, reviewed novel intervention against COVID-19. speculate that current will trigger detailed studies coronaviruses, their mechanism systematic drug repurposing approaches, discoveries future outbreaks.

Language: Английский

Citations

266